Capital Performance Advisors LLP bought a new position in Incyte Co. (NASDAQ:INCY – Free Report) in the third quarter, ...

周二，美银证券调整了对Incyte Corporation ...

Despite winning an alopecia areata approval for its drug Leqselvi in July, Sun Pharma will have to wait a while longer to ...

周二，全球投资银行公司Jefferies调整了生物制药公司Incyte Corporation (NASDAQ:INCY)的目标价。新的目标价从之前的81.00美元上调至84.00美元，同时该公司维持对该股的买入评级。这一调整是在Incyte公布的收益超出预期之后做出的，公司报告的收入为11.4亿美元，高于10.8亿美元的一致预期。

On Tuesday, Incyte Corporation (NASDAQ:INCY) reported third-quarter revenue of $1.14 billion, up 24% year over year, beating ...

Incyte’s blockbuster JAK inhibitor Jakafi has been driving the company’s sales for years now, with this quarter being no ...

Supported by world-class markets data from Dow Jones and FactSet, and partnering with Automated Insights, MarketWatch ...

On Tuesday, Incyte Corporation (NASDAQ:INCY) reported third-quarter revenue of $1.14 billion, up 24% year over year and ...

格隆汇11月5日丨康哲药业(00867.HK)公告，中华人民共和国香港特别行政区政府药剂业及毒药管理局(PPBHK)已于2024年11月4日批准磷酸芦可替尼乳膏("芦可替尼乳膏"或"产品")新药上市申请，于2024年11月5日收到药品/制品注册证明书 ...

Incyte (NASDAQ:INCY) is scheduled to announce Q3 earnings results on Tuesday, October 29th, before market open. The consensus ...

Incyte delivered robust third-quarter revenue growth, surpassing expectations, despite increased operational costs.

Supported by world-class markets data from Dow Jones and FactSet, and partnering with Automated Insights, MarketWatch ...